Company Overview - Phreesia (NYSE: PHR) provides software solutions for healthcare providers, focusing on registration, scheduling, payments, and clinical support [1] - The software enhances patient intake processes and improves overall patient experiences [1] Recent Performance - Prior to the Q3 2024 earnings report, Phreesia's stock price increased by 21.0% [1] Analyst Background - Dr. Duru, who has been blogging about financial markets since 2000, has extensive experience through various market cycles, including the dot-com bubble, financial crisis, and the coronavirus pandemic [1] - Dr. Duru's blog "One-Twenty Two" offers unique perspectives on financial markets, covering a range of topics including stocks, options, currencies, and Bitcoin [1] - The blog utilizes both technical and fundamental analysis for trading and investing strategies [1]

Phreesia (PHR) shares ended the last trading session 13.9% higher at $21.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.9% loss over the past four weeks.Phreesia scored a strong price increase, driven by investors’ optimism surrounding its impending fiscal 2025 third-quarter results, slated to be released on Dec. 9 after the closing bell. In the fiscal second quarter, Phreesia reached a crucial milestone by ...

Maskot Summary Following my coverage on Phreesia, Inc. (NYSE:PHR) in Jun'24, in which I recommended a buy rating due to my expectation that the business has no issues growing revenue at 20% given that client growth is still strong, this post is to provide an update on my thoughts on the business and stock. I remain buy-rated for PHR as the growth outlook remains solid. New logo adds remain on track to hit FY25 targets, and the increase in transaction size in the current pipeline lends credence to PHR's next ...

Phreesia (PHR) reported $102.12 million in revenue for the quarter ended July 2024, representing a year-overyear increase of 19%. EPS of -$0.31 for the same period compares to -$0.68 a year ago. The reported revenue represents a surprise of +0.35% over the Zacks Consensus Estimate of $101.76 million. With the consensus EPS estimate being -$0.37, the EPS surprise was +16.22%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

Phreesia (PHR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.22%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.51 per share when it actually produced a loss of $0.35, delivering a surprise of 31.37%. Over the last four quarters, the ...

Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to co ...

Shares of Phreesia (PHR) have gained 13.2% over the past four weeks to close the last trading session at $22.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $28.94 indicates a potential upside of 27.8%. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because t ...

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the nearterm price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically bu ...

The investigation concerns whether Phreesia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On May 30, 2024, Phreesia issued a press release announcing financial results for the first quarter of its fiscal year 2025. Among other items, Phreesia update its "revenue outlook for fiscal year 2025 to a range of $416 million to $426 million from a previous range of $424 million to $434 million." Phreesia advised that "[t]he updated revenue range ...

The investigation concerns whether Phreesia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. ("Phreesia" or the "Company") (NYSE: PHR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. [Click here for information about joining the class action] On May 30, 2024, Phr ...